Literature DB >> 27832476

Neurological and Neuropsychiatric Adverse Effects of Dermatologic Medications.

Melinda Liu1, Yuan Yu M Huang1, Sylvia Hsu2, Joseph S Kass3.   

Abstract

Severe, recalcitrant dermatologic conditions often require systemic treatment. Although efficacious, these medications have been associated with wide-ranging adverse reactions. Some are reversible, predictable, and either dose-dependent or treatment length-dependent, while others are unpredictable, irreversible, and potentially fatal. This review examines the neuropsychiatric adverse effects associated with US FDA-approved medications for treatment of the following dermatologic pathologies that typically require systemic therapy: autoimmune dermatoses, acne, psoriasis, and melanoma. A search of the literature was performed, with adverse effects ranging from mild headaches and neuropathy to severe encephalopathies. The medications associated with the most serious reactions were those used to treat psoriasis, especially the older non-biologic medications such as cyclosporine A and methotrexate. Given the importance of these systemic dermatologic therapies in treating severe, recalcitrant conditions, and the wide variety of potentially serious neuropsychiatric adverse effects of these medications, neurologists, psychiatrists, dermatologists, oncologists, and primary care providers must be aware of the potential for these neuropsychiatric adverse reactions to allow for appropriate counseling, management, and medication withdrawal.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27832476     DOI: 10.1007/s40263-016-0392-x

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  273 in total

1.  Improved overall survival in melanoma with combined dabrafenib and trametinib.

Authors:  Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  Sixth cranial nerve palsy due to acitretin.

Authors:  G J Parkins; K M Brennan; G Wylie
Journal:  Clin Exp Dermatol       Date:  2015-05-21       Impact factor: 3.470

Review 3.  Thalidomide: dermatological indications, mechanisms of action and side-effects.

Authors:  J J Wu; D B Huang; K R Pang; S Hsu; S K Tyring
Journal:  Br J Dermatol       Date:  2005-08       Impact factor: 9.302

4.  Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides.

Authors:  N Mohan; E T Edwards; T R Cupps; P J Oliverio; G Sandberg; H Crayton; J R Richert; J N Siegel
Journal:  Arthritis Rheum       Date:  2001-12

Review 5.  Current use and future potential role of retinoids in dermatology.

Authors:  C E Orfanos; C C Zouboulis; B Almond-Roesler; C C Geilen
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

6.  Improvement of Nail and Scalp Psoriasis Using Apremilast in Patients With Chronic Psoriasis: Phase 2b and 3, 52-Week Randomized, Placebo-Controlled Trial Results.

Authors:  Catherine M Nguyen; Argentina Leon; Melissa Danesh; Kourosh Beroukhim; Jashin J Wu; John Koo
Journal:  J Drugs Dermatol       Date:  2016-03       Impact factor: 2.114

7.  Depressive symptoms and suicidal ideation during isotretinoin treatment: a 12-week follow-up study of male Finnish military conscripts.

Authors:  L M H Rehn; E Meririnne; J Höök-Nikanne; E Isometsä; M Henriksson
Journal:  J Eur Acad Dermatol Venereol       Date:  2009-06-11       Impact factor: 6.166

8.  US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey.

Authors:  Mark G Lebwohl; Arthur Kavanaugh; April W Armstrong; Abby S Van Voorhees
Journal:  Am J Clin Dermatol       Date:  2016-02       Impact factor: 7.403

9.  Corticosteroid-related central nervous system side effects.

Authors:  Miriam Ciriaco; Pasquale Ventrice; Gaetano Russo; Maria Scicchitano; Giovanni Mazzitello; Francesca Scicchitano; Emilio Russo
Journal:  J Pharmacol Pharmacother       Date:  2013-12

10.  A case of intracranial hemorrhage caused by combined dabrafenib and trametinib therapy for metastatic melanoma.

Authors:  Le Min Lee; Lynn Feun; Yaohong Tan
Journal:  Am J Case Rep       Date:  2014-10-12
View more
  1 in total

1.  Management of Medication-Induced Psychiatric Disorders.

Authors:  N N Raju; K S V R Naga Pavan Kumar; Gyan Nihal
Journal:  Indian J Psychiatry       Date:  2022-03-23       Impact factor: 2.983

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.